FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000915512> ?p ?o ?g. }

• W2000915512 endingPage "266" @default.
• W2000915512 startingPage "257" @default.
• W2000915512 abstract "Prostaglandins (PG) are potent mediators of intercellular communication, and PGE2 at high concentration is immunosuppressive for T-cell-mediated immunity. We studied the kinetics of PGE2 production and the expression of the enzymes related to its synthesis during the course of experimental pulmonary tuberculosis. Secondly, we analysed the pathological and immunological changes produced by the pharmacological suppression of PG production. In BALB/c mice infected via the trachea with Mycobacterium tuberculosis H37Rv there is an initial phase of partial resistance, dominated by type 1 cytokines plus tumour necrosis factor-alpha (TNF-alpha) and expression of the inducible form of nitric oxide synthase (iNOS), followed by a phase of progressive disease. During the early phase of the infection some activated macrophages located in the alveolar-capillary interstitium and in granulomas showed strong PGE2 immunostaining. However, PGE2 concentrations were relatively low and stable. Animals in this early phase of infection were treated with niflumic acid, a potent and specific blocker of cyclo-oxygenase 2, the rate-limiting enzyme of PG production. In comparison with control animals, the suppression of PG synthesis produced higher inflammation and expression of TNF-alpha, interleukin-1alpha and interferon-gamma (IFN-gamma), but almost complete disappearance of iNOS expression, which coexisted with a significant increment of bacterial load. The late progressive phase in this experimental model is characterized by progressive pneumonia, small granulomas and diminished expression of IFN-gamma, TNF-alpha and iNOS in coexistence with high expression of IL-4. Strong PGE2 immunostaining was seen in foamy macrophages localized in the pneumonic areas, and the PGE2 concentration was four-fold higher in this late phase of infection than during the early phase. When PG production was suppressed in animals suffering advanced phase infection, a significant reduction of pneumonia and bacillus load with striking increment of granuloma size was seen, and the expression of IFN-gamma, TNF-alpha and iNOS was also improved. These findings demonstrate a significant participation of PGE2 in the pathogenesis of pulmonary tuberculosis, showing that during the early phase of the infection there are low PGE2 concentrations which contribute to iNOS expression permitting the temporal control of bacillus growth, while the high PGE2 concentrations during the late phase of the disease contribute to down-regulate cell-mediated immunity, permitting disease progression." @default.
• W2000915512 created "2016-06-24" @default.
• W2000915512 creator A5022346706 @default.
• W2000915512 creator A5035076142 @default.
• W2000915512 creator A5044466400 @default.
• W2000915512 creator A5058702726 @default.
• W2000915512 creator A5068702152 @default.
• W2000915512 creator A5090687012 @default.
• W2000915512 date "2002-06-01" @default.
• W2000915512 modified "2023-10-10" @default.
• W2000915512 title "The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis" @default.
• W2000915512 cites W1524737589 @default.
• W2000915512 cites W1536031017 @default.
• W2000915512 cites W1543251537 @default.
• W2000915512 cites W1551976873 @default.
• W2000915512 cites W1553386677 @default.
• W2000915512 cites W1554398145 @default.
• W2000915512 cites W1773327886 @default.
• W2000915512 cites W1886021042 @default.
• W2000915512 cites W1971822195 @default.
• W2000915512 cites W1974477626 @default.
• W2000915512 cites W1987175676 @default.
• W2000915512 cites W1987733838 @default.
• W2000915512 cites W2000062730 @default.
• W2000915512 cites W2003640377 @default.
• W2000915512 cites W2017021222 @default.
• W2000915512 cites W2029157550 @default.
• W2000915512 cites W2048597976 @default.
• W2000915512 cites W2065564934 @default.
• W2000915512 cites W2102340223 @default.
• W2000915512 cites W2106462617 @default.
• W2000915512 cites W2106928217 @default.
• W2000915512 cites W2111144017 @default.
• W2000915512 cites W2126043069 @default.
• W2000915512 cites W2126251148 @default.
• W2000915512 cites W2126615361 @default.
• W2000915512 cites W2158854771 @default.
• W2000915512 cites W37545008 @default.
• W2000915512 cites W56036994 @default.
• W2000915512 doi "https://doi.org/10.1046/j.1365-2567.2002.01403.x" @default.
• W2000915512 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1782721" @default.
• W2000915512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12047755" @default.
• W2000915512 hasPublicationYear "2002" @default.
• W2000915512 type Work @default.
• W2000915512 sameAs 2000915512 @default.
• W2000915512 citedByCount "121" @default.
• W2000915512 countsByYear W20009155122012 @default.
• W2000915512 countsByYear W20009155122013 @default.
• W2000915512 countsByYear W20009155122014 @default.
• W2000915512 countsByYear W20009155122015 @default.
• W2000915512 countsByYear W20009155122016 @default.
• W2000915512 countsByYear W20009155122017 @default.
• W2000915512 countsByYear W20009155122018 @default.
• W2000915512 countsByYear W20009155122019 @default.
• W2000915512 countsByYear W20009155122020 @default.
• W2000915512 countsByYear W20009155122021 @default.
• W2000915512 countsByYear W20009155122022 @default.
• W2000915512 countsByYear W20009155122023 @default.
• W2000915512 crossrefType "journal-article" @default.
• W2000915512 hasAuthorship W2000915512A5022346706 @default.
• W2000915512 hasAuthorship W2000915512A5035076142 @default.
• W2000915512 hasAuthorship W2000915512A5044466400 @default.
• W2000915512 hasAuthorship W2000915512A5058702726 @default.
• W2000915512 hasAuthorship W2000915512A5068702152 @default.
• W2000915512 hasAuthorship W2000915512A5090687012 @default.
• W2000915512 hasBestOaLocation W20009155122 @default.
• W2000915512 hasConcept C134018914 @default.
• W2000915512 hasConcept C17991360 @default.
• W2000915512 hasConcept C203014093 @default.
• W2000915512 hasConcept C204232928 @default.
• W2000915512 hasConcept C2776914184 @default.
• W2000915512 hasConcept C2777622882 @default.
• W2000915512 hasConcept C2777956040 @default.
• W2000915512 hasConcept C2778690821 @default.
• W2000915512 hasConcept C2780841837 @default.
• W2000915512 hasConcept C4224716 @default.
• W2000915512 hasConcept C519581460 @default.
• W2000915512 hasConcept C86803240 @default.
• W2000915512 hasConceptScore W2000915512C134018914 @default.
• W2000915512 hasConceptScore W2000915512C17991360 @default.
• W2000915512 hasConceptScore W2000915512C203014093 @default.
• W2000915512 hasConceptScore W2000915512C204232928 @default.
• W2000915512 hasConceptScore W2000915512C2776914184 @default.
• W2000915512 hasConceptScore W2000915512C2777622882 @default.
• W2000915512 hasConceptScore W2000915512C2777956040 @default.
• W2000915512 hasConceptScore W2000915512C2778690821 @default.
• W2000915512 hasConceptScore W2000915512C2780841837 @default.
• W2000915512 hasConceptScore W2000915512C4224716 @default.
• W2000915512 hasConceptScore W2000915512C519581460 @default.
• W2000915512 hasConceptScore W2000915512C86803240 @default.
• W2000915512 hasIssue "2" @default.
• W2000915512 hasLocation W20009155121 @default.
• W2000915512 hasLocation W20009155122 @default.
• W2000915512 hasLocation W20009155123 @default.
• W2000915512 hasOpenAccess W2000915512 @default.
• W2000915512 hasPrimaryLocation W20009155121 @default.
• W2000915512 hasRelatedWork W1971526531 @default.
• W2000915512 hasRelatedWork W1987778106 @default.

• next